This Article Full Text Full Text (PDF) Supplementary Data Supplementary Data Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Bertotti, A. Articles by Trusolino, L. Search for Related Content PubMed PubMed Citation Articles by Bertotti, A. Articles by Trusolino, L.

ß₄ Integrin Is a Transforming Molecule that Unleashes Met Tyrosine Kinase Tumorigenesis

Division of Molecular Oncology, Institute for Cancer Research and Treatment (IRCC), University of Torino School of Medicine, Candiolo (Torino), Italy

Requests for reprints: Livio Trusolino, Division of Molecular Oncology, Institute for Cancer Research and Treatment (IRCC), University of Torino School of Medicine, Strada Provinciale 142, km 3.95, 10060 Candiolo, Turin, Italy. Phone: 39-11-993-3202; Fax: 39-11-993-3225; E-mail: livio.trusolino{at}ircc.it.

Cell multiplication in the absence of integrin-derived adhesive signals (anchorage-independent growth) is the phenotypic hallmark of neoplastic transformation. Therefore, the frequently observed up-regulation of some integrins in tumors has been interpreted as an epiphenomenon and not as a causative factor of oncogenic conversion. ß₄ integrin stimulates proliferation and survival of epithelial cells and is overexpressed in human carcinomas, often in concomitance with up-regulation of the Met tyrosine kinase receptor for hepatocyte growth factor. Met is not endowed with transforming ability but can exploit the ß₄ cytoplasmic tail as a substrate/adaptor for amplification of mitogenic and antiapoptotic responses, independently of cell adhesion. Here, we show that overexpression of ß₄ is sufficient to transform rodent fibroblasts, enhances anchorage-independent growth of breast carcinoma cells, and induces tumorigenesis in nude mice; conversely, RNA interference–mediated depletion abrogates the transformed phenotype of neoplastic cells. These autonomous oncogenic properties are dramatically exacerbated upon Met coexpression, suggesting that the integrin can instigate the latent tumorigenic potential of the kinase. A ß₄ nonadhesive variant still cooperates with Met for cellular transformation, confirming the adhesion-independent function of ß₄ in magnification of Met biological effects. Conversely, a ß₄ signaling-incompetent mutant that cannot be efficiently tyrosine phosphorylated by Met and displays reduced ability to activate phosphatidylinositol 3-kinase–dependent and Ras-dependent pathways aborts transformation. Our findings define ß₄ as a signaling accomplice (a "servo-oncogene") of tyrosine kinase proto-oncogenes in primary carcinogenesis, evoke an unorthodox function for a prototypic adhesion molecule in the positive regulation of anchorage-independent growth, and suggest the use of ß₄ as a target for anticancer therapy.

This article has been cited by other articles:

				T. H. Kim, H. I. Kim, Y. H. Soung, L. A. Shaw, and J. Chung Integrin ({alpha}6{beta}4) Signals Through Src to Increase Expression of S100A4, a Metastasis-Promoting Factor: Implications for Cancer Cell Invasion Mol. Cancer Res., October 1, 2009; 7(10): 1605 - 1612. [Abstract] [Full Text] [PDF]

				G. Bon, S. E. Di Carlo, V. Folgiero, P. Avetrani, C. Lazzari, G. D'Orazi, M. F. Brizzi, A. Sacchi, S. Soddu, G. Blandino, et al. Negative Regulation of {beta}4 Integrin Transcription by Homeodomain-Interacting Protein Kinase 2 and p53 Impairs Tumor Progression Cancer Res., July 15, 2009; 69(14): 5978 - 5986. [Abstract] [Full Text] [PDF]

				M. Chen, M. Sinha, B. A. Luxon, A. R. Bresnick, and K. L. O'Connor Integrin {alpha}6{beta}4 Controls the Expression of Genes Associated with Cell Motility, Invasion, and Metastasis, Including S100A4/Metastasin J. Biol. Chem., January 16, 2009; 284(3): 1484 - 1494. [Abstract] [Full Text] [PDF]

				L. Yang, L. Zhang, Q. Wu, and D. D. Boyd Unbiased Screening for Transcriptional Targets of ZKSCAN3 Identifies Integrin {beta}4 and Vascular Endothelial Growth Factor as Downstream Targets J. Biol. Chem., December 12, 2008; 283(50): 35295 - 35304. [Abstract] [Full Text] [PDF]

				Y. Hao, A. Chun, K. Cheung, B. Rashidi, and X. Yang Tumor Suppressor LATS1 Is a Negative Regulator of Oncogene YAP J. Biol. Chem., February 29, 2008; 283(9): 5496 - 5509. [Abstract] [Full Text] [PDF]

				V. Patel, B. L. Hood, A. A. Molinolo, N. H. Lee, T. P. Conrads, J. C. Braisted, D. B. Krizman, T. D. Veenstra, and J. S. Gutkind Proteomic Analysis of Laser-Captured Paraffin-Embedded Tissues: A Molecular Portrait of Head and Neck Cancer Progression Clin. Cancer Res., February 15, 2008; 14(4): 1002 - 1014. [Abstract] [Full Text] [PDF]

				V. Folgiero, R. E. Bachelder, G. Bon, A. Sacchi, R. Falcioni, and A. M. Mercurio The {alpha}6{beta}4 Integrin Can Regulate ErbB-3 Expression: Implications for {alpha}6{beta}4 Signaling and Function Cancer Res., February 15, 2007; 67(4): 1645 - 1652. [Abstract] [Full Text] [PDF]

				A. Bertotti, P. M. Comoglio, and L. Trusolino {beta}4 integrin activates a Shp2-Src signaling pathway that sustains HGF-induced anchorage-independent growth J. Cell Biol., December 18, 2006; 175(6): 993 - 1003. [Abstract] [Full Text] [PDF]

				M. Mazzone and P. M. Comoglio The Met pathway: master switch and drug target in cancer progression FASEB J, August 1, 2006; 20(10): 1611 - 1621. [Abstract] [Full Text] [PDF]

				K. Wilhelmsen, S. H.M. Litjens, and A. Sonnenberg Multiple Functions of the Integrin {alpha}6{beta}4 in Epidermal Homeostasis and Tumorigenesis Mol. Cell. Biol., April 15, 2006; 26(8): 2877 - 2886. [Full Text] [PDF]